WuXi PharmaTech Receives Belgium GLP Statement

WuXi PharmaTech’s toxicology facility in Suzhou has received a statement of GLP from the Belgium Scientific Institute of Public Health following two successful GLP inspections conducted by the Belgium GLP Monitorate. The GLP statement acknowledges the capability to carry out toxicology and mutagenicity studies and analytical and clinical chemistry testing with respect to OECD and EC principles of GLP.

The inspection included an audit of 16 studies in areas that included general toxicology, genetic toxicology, safety pharmacology, dermal irritation, skin phototoxicity, and immunology. The facility inspection evaluated key operational sites, including the vivarium rooms, pharmacy, central archive, and laboratories relating to analytical chemistry, bioanalytical services, toxicokinetics, clinical pathology, histopathology, and immunology.   

“WuXi’s receipt of this statement is further acknowledgment that we offer our pharmaceutical and biotech clients toxicology studies that meet international GLP quality standards,” said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. “With this award, WuXi moves a step closer to achieving its goal of offering our clients a comprehensive, fully integrated platform of pharmaceutical R&D services.”